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Fibrotic gingival enlargements induced by phenytoin or nifedipine were examined with special reference to type VI collagen expression. Immuno- 
localization studies howed abnormal accumulation of type VI collagen around the collagen fiber bundles in the fibrotic gingival enlargements. 
Examination of total RNA extracted from fibroblasts and tissues of enlarged gingivae demonstrated increased type VI collagen steady-state mRNA 
levels. These results suggest that excessive deposition of type VI collagen in drug-induced gingival enlargement is attributed to increased expression 
of the collagen genes. 
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1. INTRODUCTION 
Gingival enlargement is an intractable disease caused 
by an uncontrolled fibrous overgrowth of the gingival 
tissue and often leads to periodontitis which is a major 
cause of tooth loss. The disease can be a hereditary 
condition, i.e. familiar gingival fibromatosis, or it may 
occur as a side effect of several drugs including 
phenytoin (PHT) for the treatment of epilepsy, nifedip- 
ine (NF) for the treatment of cardiac angina and ven- 
tricular arrhythmias and cyclosporin for immunosup- 
pression therapy. In recent years, the number of pa- 
tients with this disease has increased because of in- 
creased administration of these drugs. Although the 
mechanism of drug-induced gingival enlargement is not 
known, several lines of evidence have suggested that in 
most cases overproduction of the fibrillar collagens by 
gingival fibroblasts contributes to excessive collagen 
deposition in the gingiva [1-3]. 
Recent studies on the structure and function of colla- 
gens have identified at least 15 distinct collagen types 
[4], and demonstrated that the imbalance between the 
synthesis and degradation f the collagens causes vari- 
ous human diseases. Type VI collagen which is com- 
posed of three different c~ chains, denoted as cO(VI), 
~2(VI) and c~3(VI), is a ubiquitous component in many 
tissues of the body including normal gingiva [5,6]. Re- 
cently, non-co-ordinated regulation of gene expression 
of the three type VI collagen chains has been observed 
for some tumor cells [7] and in human skin fibroblasts 
grown in collagen gels [8] or treated with ),-interferon 
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[9]. Although increased synthesis or deposition of this 
collagen is implicated in fibrotic conditions including 
liver fibrosis [10], scleroderma [11] and fibrous tumors 
such as neurofibroma [12] and cutaneous fibromatosis 
[13], no quantitative information is available measuring 
tissue-specific variation in mRNA levels or the changes 
in the mRNA levels that occur in these fibrotic condi- 
tions. 
In this report we demonstrate for the first time that 
the steady-state level of type VI collagen mRNA is sig- 
nificantly increased in gingival fibroblasts and tissue 
extracts from drug-induced gingival enlargements. We 
also show that type VI collagen is intensely immunolo- 
calized around the thick collagen fiber bundles and 
blood vessels in samples of drug-induced gingiva. 
2. MATERIALS AND METHODS 
2.1. Immunohistochemistry 
The fibrotic gingival samples were surgically removed from a total 
of 11 patients with drug-induced gingival enlargement. In seven pa- 
tients the gingival enlargement was due to PHT and in four cases due 
to NF treatment. Control gingiva was obtained from comparable 
areas of gingiva from 12 healthy individuals undergoing dental surgery 
for various benign ingival lesions. These samples were us d for the 
experiments after informed consent. Sections of formalin-fixed and 
paraffin-embedded tissue specimens were prepared for histopathology 
and immunohistochemistry. Immunohistochemistry of t pe I, III and 
VI collagens was performed by an avidin-biotin peroxidase method 
with protease digestion as previously described [14]. As a control, 
normal rat or rabbit serum diluted at 1:10 to 1:100 was applied insten,~ 
of the primary antibodies. 
2.2. Cell cultures 
Gingival fibroblasts were cultured from six gingival tissues (two 
PHT- and two NF-induced gingival enlargement samples and two 
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control samples). The cells were grown in Dulbecco's modified Eagle's 
medium containing 10% fetal calf serum, 100/zg/ml penicillin a d 100 
/lg/ml streptomycin at 37°C in an atmosphere of 5%CO2195% air and 
used at passages 4-7. 
2.3. Northern blot and slot blot analyses 
Total RNA was isolated from cultured cells and gingival tissues a
described previously [15,16]. Poly (A) ÷ RNA was obtained from total 
RNA using the Poly(A) Quick mRNA Isolation Kit (Stratagene, La 
Jolla, CA) according to the manufacturer's in tructions. For Northern 
blot analysis, either total or poly(A)+RNA was size-fractionated on 
1% denaturating a arose-formaldehyde gels and transferred onto ni- 
trocellulose filters. The filters were hybridized with [~-32P]dCTP-la- 
beled cDNA probes; p18 coding for ~I(VI), pl for ~2(VI), p24 for 
cc3(VI) [7], pHFbA for fl-actin [17]. For slot blot hybridization, total 
RNA was applied onto nitrocellulose filters in various concentrations 
and the filters were hybridized with radioactive cDNAs utilizing the 
same conditions employed for the Northern blot analysis, and fol- 
lowed by fluorography at -80°C. 
3. RESULTS 
All eleven gingival enlargement samples showed 
subepithelial fibrous overgrowth comprised of thick 
collagen fiber bundles and focal infiltration of chronic 
inflammatory cells. In advanced cases, collagen fiber 
bundles had hyalinization. Twelve control specimens 
appeared normal except for the presence of focal in- 
flammatory cell infiltration. Immunolocalization 
showed that type VI collagen is localized in the juxtaep- 
ithelium of papillae and in smaller amounts around the 
small blood vessels in normal gingiva (Fig. 1A). In con- 
trast, type VI collagen showed a broad and intense dis- 
tribution around thick collagen fiber bundles as well as 
in and around the juxtaepithelium and small blood ves- 
sels in the drug-induced gingival enlargement (Fig. 1B). 
The labeling was extremely strong around the hy- 
alinized collagen fiber bundles (Fig. 1C). Thick collagen 
fibers in the enlarged gingivae were diffusely im- 
munostained with anti-(type I collagen) antibodies and 
faintly positive with anti-(type III collagen) antibodies 
(data not shown). 
Steady-state levels of mRNA encoding the three indi- 
vidual 0~ chains of type VI collagen were determined by 
Northern blot and slot blot hybridization. Fig. 2 is a 
representative Northern blot analysis, showing the ex- 
pression of the ~I(VI), ~2(VI) and ~3(VI) genes in fi- 
broblasts derived from normal control and drug-in- 
duced enlarged gingivae. The ratio of the amount of 
Fig. 1. Immunolocalization f type VI collagen in normal gingiva and PHT-induced gingival enlargement. The areas in the juxtaepithelium of 
papillae (arrows) are labeled with the antibodies inthe normal gingiva (A). Note the intense localization around the collagen fiber bundles, especially 
those with hyalinization (enclosed area) and blood vessels in the gingival enlargement (B,C). A, × 135; B, x 35; C, higher magnification view of 
the area enclosed by a rectangle, x 175. 
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mRNA for the c~ chains of type VI collagen to that of 
fl-actin in the gingival enlargement samples was in- 
creased approximately twofold compared with the con- 
trol, and the levels of the fl-actin mRNA in these sam- 
ples were found to be essentially the same in control and 
enlarged gingivae (Fig. 2). When the relative abundance 
of 0d(VI), ~2(VI) and ~3(VI) mRNAs present in the 
tissue extracts from the enlarged gingivae was com- 
pared with that from the control gingiva by slot blot 
hybridization, the levels were two- to sevenfold (4 + 0.6; 
mean + S.D.) higher in the enlarged gingivae than in the 
control (Fig. 3). In contrast, the levels of the fl-actin 
mRNA in the control and enlarged gingivae were found 
to be essentially the same, suggesting a selective increase 
of type VI collagen genes in the gingival enlargement. 
4. DISCUSSION 
Our studies presented here demonstrate for the first 
time the enhanced expression of type VI collagen genes 
and excessive deposition of the collagen in enlarged 
fibrous gingiva caused by PHT or NF therapy. Immu- 
nohistochemistry of type VI collagen in enlarged 
gingiva suggests that it is closely associated with dense 
and hyalinized fibroses which are composed mainly of 
type I and type III collagens [18]. Similar colocalization 
has been reported in hypertrophied ligamentum flavum 
[191. 
It has been suggested hat the [~I(VI) ~2(VI) ~3(VI)] 
heterotrimer is the type VI collagen monomer with max- 
imum intra or intermolecular disulphide-bonding and 
highest stability, and that aggregates comprised of mon- 
omers with different chain compositions are less stable 
entities with enhanced susceptibility o protease attack 
[20]. Since all three type VI collagen ~ chain transcripts 
were significantly increased in the extracts from the en- 
larged gingiva tissues, the excessive gingival deposition 
can be attributed to increased synthesis of heterotrimers 
composed of these type VI collagen chains. Immunolo- 
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Fig. 2. Northern blot analysis of type VI collagen gene expression i  
the fibroblasts from normal (lane 1) and PHT-enlarged gingiva (lane 
2). Two micrograms of poly(A) ÷ RNA were employed in the analysis. 
The positions of 28 S and 18 S rRNA are indicated as size markers. 
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Fig. 3. Slot blot hybridization of total RNA from the gingival tissues. 
Various amounts of RNA, 1.25-10 pg, were dotted onto nitrocellulose 
filters and were hybridized with cDNA probes. Density of the bands 
was measured by scanning densitometry. 
calization studies on type VI collagen did not identify 
the cells synthesizing type VI collagen. However, the 
data from Northern blot analyses howing increased 
expression of the genes for type VI collagen in fibro- 
blasts isolated from gingival tissues uggest that stromal 
fibroblasts are responsible for the overproduction. 
One of the properties of type VI collagen is to func- 
tion as a linking element between other larger morphol- 
ogic structures, uch as basement membranes of nerves 
and blood vessels [21], or collagen fiber bundles [22]. 
This function suggested by the immunolocalization 
studies agrees with the analysis of the type VI collagen 
cDNA sequence which encodes globular domains con- 
taining many repeats of a structure similar to the colla- 
gen-binding A domains of von Willebrand factor 
[23,24]. Therefore, it seems likely that type VI collagen 
localized around the thick collagen fiber bundles and 
blood vessels in the gingival enlargement may contrib- 
ute to the structural deformity seen in the pathological 
condition. With the development of hypertrophic 
changes, the gingiva is frequently exposed to bacterial 
infection which induces inflammatory reactions. This 
creates a condition with overproduction of the pro- 
teinases derived from bacteria, inflammatory cells and 
tissue cells. However, type VI collagen is resistant to 
bacterial collagenase and matrix metalloproteinases 
(MMP) including MMP-1 (interstitial collagenase), 
MMP-2 (72 kDa gelatinase/type IV collagenase), 
MMP-3 (stromelysin-1) and MMP-9 (92 kDa gelati- 
nase/type IV collagenase) [25,26], all of which can digest 
other types of collagen. Thus, type VI collagen could 
remain in the tissue even in the inflammatory condi- 
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tions. The resistance of  type VI collagen to proteinases, 
in addit ion to its overproduct ion,  may be responsible 
for the accumulated eposit ion of  type VI collagen in 
enlarged gingivae. 
The mechanism by which PHT and NF  causes over- 
product ion of  the collagens is still obscure. It has been 
reported that the steady-state l vels of  type I collagen 
mRNA are increased in gingival f ibroblasts cultured 
from enlarged gingival tissue [2] or in cultured fibro- 
blasts treated with the drug [1]. These data suggest he 
possibil ity that the drugs directly up-regulate the ex- 
pression of  the col lagen genes. However, f ibrous over- 
growth is known to become worse when inf lammation 
is super imposed on gingival enlargement, suggesting 
that cytokines and growth factors derived from the in- 
f lammatory cells st imulate the stromal cells to produce 
collagen. Transforming rowth factor f l l  is a good can- 
didate, since it st imulates type I and I I I  col lagen gene 
expression in f ibroblasts, and elevated expression of  the 
growth factor and type VI collagen genes has been 
shown by means of  in situ hybr idizat ion in the diffuse 
fasciitis [27]. Fur ther  work is needed to elucidate the 
mechanisms regulating collagen gene expression in en- 
larged gingivae. 
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